SIGNIFICANT ONGOING CLINICAL TRIALS

Definitive, Late Phase Trials

Phase 3 Trial in Advanced Non-Small Cell Lung Cancer Will Assess FDG-PET/CT as Predictive Marker of Response and Patient Outcome

http://www.cancer.gov/clinicaltrials/ACRIN-6678

ACRIN is conducting a study, ACRIN 6678, to prospectively validate FDG-PET in conjunction with computed tomography (CT) as a predictive marker of response and patient outcome in patients with advanced NSCLC. This study was activated in March 2007 and is the result of a joint effort between CTEP, DCTD’s CIP, the FDA, and the Centers for Medicare and Medicaid under the Oncology Biomarker Qualification Initiative. This study may have an impact on how new targeted therapies are applied to patients with lung cancer.